Cyclo Therapeutics Shares Jump After Filing To Start Alzheimer's Trial In US

Vandana Singh , Benzinga Staff Writer

November 16, 2021 11:21am Comments

Cyclo Therapeutics Inc (NASDAQ: CYTH) has submitted its initial investigational new drug (IND) application with the FDA for a Phase 2 study of Trappsol Cyclo for early Alzheimer's Disease (AD).
Related Link: Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder.
The Company says that biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's Disease bolster rationale for studying Trappsol for early Alzheimer's Disease.
Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta-cyclodextrin.
Related content: Benzinga's Full FDA Calendar.
Price Action: CYTH shares are up 2.23% at $7.45 during the market session on the last check Tuesday.

Posted-In: Alzheimer Biotech News Health Care FDA Movers Trading Ideas General

1	ASTS, FRHC: Rocket Lab, AST SpaceMobile And Circle Internet Are Among Top 10 Large...
2	$DOGE: Dogecoin Set To Soar 2,600% and Hit $1 Trillion Market Cap, Says...
3	AMZN, META: Disruption In Browsers, Amazon's AI Job Requiremen...
4	E, ASML: Schlumberger, Stellantis And ASML Holding Are Am...
5	Trump Ally Jair Bolsonaro Hit With Restraining O...
6	Bolsonaro's Restraining Order, Gates'...
7	The Trumps, Bitcoin Bull Run And Stablecoin Bill...

1	Senators' $1.5 Trillion Plan Promises To Save Social Security Without Cutti...
2	This Car Owner Considers Borrowing From Their 401(k) To Make Car Payments—Is I...
3	Kevin O'Leary Advocates Entrepreneurship Over Consulting to Students: '...
4	Forget 'Wealth': Warren Buffett Says This Word Is the True Measure of...
5	Elon Musk Returns To Intense Work Schedule: 'Back To Working 7 Days a Week...
6	Trump Administration's Attempt To Cut Elon Musk's SpaceX Contracts Thw...
7	FICO: FICO To Roll Out New Scores to Reflect Your "Buy Now, Pay Later" H...

Market Overview